改善心肌肌质网钙泵防治慢性心力衰竭的中医药研究进展

Abstract
Figure/Table
References (24)
Related Citation (15)

Download: PDF (612 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Chronic heart failure (CHF ) is the end stage of a variety of cardiovascular diseases, with high incidence, high mortality and expensive treatment. The abnormal expression and activity of cardiac myocyte sarcoplasmic reticulum calcium ATPase 2a (SERCA2a) are the key pathological mechanism for the occurrence and development of CHF. The results of the clinical trial that AAV1/SERCA2a genetically treats CHF were not satisfactory, and the researchers restated that full attention should be paid to drug screening, research and development to improve the endogenous myocardial SERCA2a expression level and activity. Traditional Chinese medicine has a long history in treating CHF with remarkable therapeutic effects. In traditional Chinese medicine, CHF can be classified to the cotogories of "palpitation", "asthma syndrome" and "edema". A lot of researches indicate that Chinese medicine compound, single Chinese herb and Chinese medicine monomer can prevent and treat CHF through improving endogenous myocardial SERCA2a expression and activity.

Key words： Chronic heart failure Sarcoplasmic reticulum calcium ATPase 2a Protein expression Gene expression Activity

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LI Huiling JIA Meijun LIU Yongming

Cite this article:

LI Huiling JIA Meijun LIU Yongming. Research progress on improving myocardial sarcoplasmic reticulum calcium ATPase 2a with the treatment of traditional Chinese medicine in chronic heart failure[J]. 中国医药导报, 2019, 16(4): 55-58.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2019/V16/I4/55

[1] Mora MT，Ferrero JM，Romero L，et al. Sensitivity analysis revealing the effect of modulating ionic mechanisms on calcium dynamics in simulated human heart failure [J]. PLoS One，2017，12（11）：e0187739.
[2] Sacchi V，Wang BJ，Kubli D，et al. Peptidyl-Prolyl Isomerase 1 Regulates Ca2+ Handling by Modulating Sarco（Endo）Plasmic Reticulum Calcium ATPase and Na2+/Ca2+ Exchanger 1 Protein Levels and Function [J]. J Am Heart Assoc，2017，6（10）：e006837.
[3] Gorski PA，Ceholski DK，Hajjar RJ. Altered myocardial calcium cycling and energetics in heart failure--a rational approach for diseasetreatment [J]. Cell Metab，2015，21（2）：183-194.
[4] Hu LR，Ackermann MA，Hecker PA，et al. Deregulated Ca2+ cycling underlies the development of arrhythmia and heart disease due to mutant obscurin [J]. Sci Adv，2017，3（6）：e1603081.
[5] 刘永明，徐裕亚，那木海，等.坎离颗粒对压力负荷超载所致舒张性心衰大鼠心肌肌浆网钙转运的影响[J].中医杂志，2015，56（21）：1867-1870.
[6] Wang Q，Liu Y，Fu Q，et al. Inhibiting Insulin-Mediated β2-Adrenergic Receptor Activation Prevents Diabetes-Associated Cardiac Dysfunction [J]. Circulation，2017，135（1）：73-88.
[7] Silveira CFSMP，Campos DHS，Freire PP，et al. Importance of SERCA2a on early isolated diastolic dysfunction induced by supravalvular aortic stenosis in rats [J]. Braz J Med Biol Res，2017，50（5）：e5742.
[8] Jaski BE，Jessup ML，Mancini DM，et al. Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease（CUPID Trial），a First-in-Human Phase 1/2 Clinical Trial [J]. J Card Fail，2009，15（3）：171-181.
[9] Hulot JS，Salem JE，Redheuil A，et al. Effect of intracoronary administration of AAV1/SERCA2a on ventricular remodelling in patients with advanced systolic heart failure：results from the AGENT-HF randomized phase 2 trial [J]. Eur J Heart Fail，2017，19（11）：1534-1541.
[10] Greenberg B，Butler J，Felker GM，et al. Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease（CUPID 2）：a randomized，multinational，double-blind，placebo-controlled，phase 2b trial [J]. Lancet，2016，387（10024）：1178-1186.
[11] 连志明，权力，刘明鑫，等.稳心颗粒对心力衰竭兔心肌细胞肌浆网钙泵基因和蛋白表达的影响[J].中国心脏起搏与心电生理杂志，2014，28（6）：527-531.
[12] 郭志华，吴刚强，申思，等.益心泰对慢性心力衰竭大鼠心肌钙超载及肌浆网钙泵的影响[J].中国中医药现代远程教育，2013，3（155）：157-159.
[13] 吴锦波，叶小汉，冼绍祥，等.中药心康方对心力衰竭大鼠心肌miR-25-3p表达水平和SERCA2a活性的影响[J].中国病理生理杂志，2016，32（10）：1770-1774.
[14] Yu X，Zhao XD，Bao RQ，et al. The modified Yi qi decoction protects cardiac ischemia-reperfusion induced injury in rats [J]. BMC Complement Altern Med，2017， 17（1）：330.
[15] 青楚杭.芪苈强心提取物下调microRNA-25改善缺氧诱导的心肌细胞损伤[D].南充：川北医学院，2017.
[16] 苗梦露，李七一，严士海，等.抗心衰颗粒对舒张性心衰大鼠模型心肌细胞内钙离、ATP酶及心肌线粒体超微结构的影响[J].北京中医药大学学报，2013，36（7）：468-471.
[17] 张萍，王海云，苏博，等.延胡索提取物对AMI大鼠模型心肌梗死面积及Na+-K+-ATPase、Ga2+-ATPase活性的影响[J].中西医结合心脑血管病杂志，2017，15（4）：410-415.
[18] Dong Z，Zhao P，Xu M，et al. Astragaloside Ⅳ alleviates heart failure via activating PPARα to switch glycolysis to fatty acid β-oxidation [J]. Sci Rep，2017，7（1）：2691.
[19] Bai T，Hu X，Zheng Y，et al. Resveratrol protects against Lipopolysaccharide-induced cardiac dysfunction by enhancing SERCA2a activity through promoting the phospholamban oligomerization [J]. Am J Physiol Heart Circ Physiol，2016，311（4）：H1051-H1062.
[20] 戴红良，贾桂枝，赵颂，等.黄芪多糖对异丙肾上腺素诱发的SERCA2a表达及活性降低的影响[J].中国药理学通报，2015，31（3）：388-391.
[21] 王俊东，崔勇，王建国，等.人参皂苷Rh3预处理对心肌缺血再灌注损伤大鼠心肌肌浆网Ca2+-ATP酶表达的影响[J].中华老年心脑血管病杂志，2016，18（10）：1077-1081.
[22] 王金桂，祝宝华，于晓頔，等.前胡丙素对大鼠缺血-再灌注心肌肌浆网钙泵功能及其蛋白水平的影响[J].江苏医药，2015，41（2）：138-141.
[23] Wu X，Xu T，Li D，et al. ERK/PP1a/PLB/SERCA2a and JNK Pathways Are Involved in Luteolin-Mediated Protection of Rat Hearts and Cardiomyocytes following Ischemia/Reperfusion [J]. PLoS One，2013，8（12）：e82957.
[24] Du Y，Liu P，Xu T，et al. Luteolin Modulates SERCA2a Leading to Attenuation of Myocardial Ischemia/Reperfusion Injury via Sumoylation at Lysine 585 in Mice [J]. Cell Physiol Biochem，2018，45（3）：883-898.